Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

This study has been completed.

Study NCT00049192 Information provided by Cancer and Leukemia Group B

First Received: November 12, 2002 Last Updated: March 8, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	April 2009
Primary Completion Date:	November 2005 (Final data collection date for primary outcome measure)

Publications:

Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia - Cancer and leukemia group B study 10107. Leuk Lymphoma. 2008 Apr 4;:1-5 [Epub ahead of print]

Back to top of Main Content